Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe

Phase 1

Completed

• Conditions: Dyslipidemia
• Interventions: Drug: NVP-1205; Drug: rosuvastatin and ezetimibe

• Registration Number: NCT02029625
• Lead Sponsor: NVP Healthcare

Brief Summary

The purpose of this study is to compare the pharmacokinetics of NVP-1205 and coadministration of rosuvastatin and ezetimibe.

Detailed Description

rosuvastatin and ezetimibe(anti-dyslipidemia)

Study Timeline

• Study First Submitted: 2014-01-05
• Study First Submitted QC: 2014-01-06
• Study First Posted: 2014-01-08
• Study Start: 2014-02
• Primary Completion: 2014-03
• Study Completion: 2014-03
• Status Verified: 2016-03
• Last Update Submitted: 2016-03-24
• Last Update Posted: 2016-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 41

Inclusion Criteria

• Healthy male subjects age between 19 and 55 signed informed consent

Exclusion Criteria

• subjects have a history of allergy reaction of this drug or other drugs

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
NVP-1205	NVP-1205	administration of NVP-1205(rosuvastatin+ezetimibe)
rosuvastatin and ezetimibe	rosuvastatin and ezetimibe	coadministration of rosuvastatin and ezetimibe

Primary Outcome Measures

Name	Time	Method
AUClast	0-96hr

Secondary Outcome Measures

Name	Time	Method
AUCinf	0-96hr

Trial Locations

Locations (1)

Kyungpook National Hospital; 🇰🇷 Jung-gu, Daegu, Korea, Republic of

Kyungpook National Hospital

🇰🇷Jung-gu, Daegu, Korea, Republic of